Avandia Day Two Might Be Same Old Song Even With Broken RECORD

There may be more at stake for FDA, and the pharmaceutical industry in general, in how the advisory committees interpret the RECORD trial than there is for Avandia itself.

More from Archive

More from Pink Sheet